Online inquiry

IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10933MR)

This product GTTS-WQ10933MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets HAVCR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_032782.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 84868
UniProt ID Q8TDQ0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ10933MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4596MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986015
GTTS-WQ4537MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ1344MR IVTScrip™ mRNA-Anti-EGFR, ABT-806(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-806
GTTS-WQ1242MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ14728MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ5734MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ8922MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ1828MR IVTScrip™ mRNA-Anti-CFD, AFD Anti-fD(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AFD Anti-fD
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW